摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5α)-19-hydroxy-androstane-3,17-dione cyclic bis-(1,2-ethanediyl acetal) | 2220-69-1

中文名称
——
中文别名
——
英文名称
(5α)-19-hydroxy-androstane-3,17-dione cyclic bis-(1,2-ethanediyl acetal)
英文别名
——
(5α)-19-hydroxy-androstane-3,17-dione cyclic bis-(1,2-ethanediyl acetal)化学式
CAS
2220-69-1
化学式
C23H36O5
mdl
——
分子量
392.536
InChiKey
YNAYKNYSMOPCAN-HXIANDDZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    28
  • 可旋转键数:
    1
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    57.2
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] STÉROÏDES NEUROACTIFS, COMPOSITIONS ET UTILISATIONS
    申请人:SAGE THERAPEUTICS INC
    公开号:WO2015027227A1
    公开(公告)日:2015-02-26
    Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R1, R2, R5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    本文描述了化学式(I)中的神经活性类固醇或其药用可接受盐;其中-------,R1,R2,R5,A和L如本文所定义。在某些实施例中,预期这些化合物将表现为GABA调节剂。本发明还提供了包括本发明化合物的药物组合物以及使用和治疗方法,例如用于诱导镇静和/或麻醉的方法。
  • NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS
    申请人:WASHINGTON UNIVERSITY
    公开号:US20140249120A1
    公开(公告)日:2014-09-04
    The present disclosure is generally directed to neuroactive 13,17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    本公开涉及神经活性的13,17-取代类固醇,以及其药用盐,例如作为麻醉剂使用,和/或用于治疗与GABA功能和活性相关的疾病。本公开还涉及包含这些化合物的药物组合物。
  • [EN] NEUROACTIVE 19-ALKOXY-17(20)-Z-VINYLCYANO-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME<br/>[FR] STÉROÏDES NEUROACTIFS 19-ALCOXY-17(20)-Z-VINYLCYANO-SUBSTITUÉS, PROMÉDICAMENTS ASSOCIÉS ET MÉTHODES DE TRAITEMENT LES UTILISANT
    申请人:UNIV WASHINGTON
    公开号:WO2014058736A1
    公开(公告)日:2014-04-17
    The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    本公开涉及神经活性19-烷氧基-17(20)-Z-乙烯基氰基取代类固醇,以及其药学上可接受的盐,例如用作麻醉剂和/或治疗与GABA功能和活性相关的疾病。本公开还涉及包含这些化合物的药物组合物。
  • NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
    申请人:SAGE THERAPEUTICS, INC.
    公开号:US20160229887A1
    公开(公告)日:2016-08-11
    Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R 1 , R 2 , R 5 , A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    本文描述了式(I)的神经活性类固醇或其药学上可接受的盐;其中-------,R1,R2,R5,A和L的定义如下。在某些实施方式中,这些化合物被认为是GABA调节剂。本发明还提供了包含本发明化合物的制药组合物以及使用和治疗方法,例如用于诱导镇静和/或麻醉。
  • NEUROACTIVE 19-ALKOXY-17(20)-Z-VINYLCYANO-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME
    申请人:Washington University
    公开号:US20150259376A1
    公开(公告)日:2015-09-17
    The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
查看更多